| Literature DB >> 28208616 |
Rory C F Brito1,2, Frederico G Guimarães3, João P L Velloso4, Rodrigo Corrêa-Oliveira5,6, Jeronimo C Ruiz7,8, Alexandre B Reis9,10,11, Daniela M Resende12,13.
Abstract
Leishmaniasis is a wide-spectrum disease caused by parasites from Leishmania genus. There is no human vaccine available and it is considered by many studies as apotential effective tool for disease control. To discover novel antigens, computational programs have been used in reverse vaccinology strategies. In this work, we developed a validation antigen approach that integrates prediction of B and T cell epitopes, analysis of Protein-Protein Interaction (PPI) networks and metabolic pathways. We selected twenty candidate proteins from Leishmania tested in murine model, with experimental outcome published in the literature. The predictions for CD4⁺ and CD8⁺ T cell epitopes were correlated with protection in experimental outcomes. We also mapped immunogenic proteins on PPI networks in order to find Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with them. Our results suggest that non-protective antigens have lowest frequency of predicted T CD4⁺ and T CD8⁺ epitopes, compared with protective ones. T CD4⁺ and T CD8⁺ cells are more related to leishmaniasis protection in experimental outcomes than B cell predicted epitopes. Considering KEGG analysis, the proteins considered protective are connected to nodes with few pathways, including those associated with ribosome biosynthesis and purine metabolism.Entities:
Keywords: epitope prediction; immunoinformatics; leishmaniasis; pathways; protein–protein interaction networks; reverse vaccinology
Mesh:
Substances:
Year: 2017 PMID: 28208616 PMCID: PMC5343906 DOI: 10.3390/ijms18020371
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Selected candidate antigens from dermatotropic and visceratropic Leishmania species to leishmaniasis vaccine development. Proteins in literature tested in mice model were selected randomly.
| Geographic Area | Specie | Candidate Antigen | Function | MySQL ID | NCBI Sequence Acession | Animal | Experimental Outcome Indicative | Reference | |
|---|---|---|---|---|---|---|---|---|---|
| New world | Thiol-specific-antioxidant (TSA) | Tryparedoxin peroxidase | LbrM.15.1080 | gi 154334618 | mice | No protection | [ | ||
| LeiF | LbrM.25.0580 | gi 154338682 | mice | No protection | [ | ||||
| LACK | LbrM.28.2950 | gi 154340729 | mice | Partial protection | [ | ||||
| P4 nuclease partial | Endonuclease activity | A16600 | gi 29165287 | mice | No protection | [ | |||
| Cysteine proteinase | Cysteine-type peptidase activity | A22180 | gi 30142572 | mice | Partial protection | [ | |||
| HSP20 | Heat shock protein | A38570 | gi 513044555 | mice | No protection | [ | |||
| GP46 | Membrane glycoprotein | A64110 | gi 159321 | mice | Protection | [ | |||
| GP63 | Metalloendopeptidase activity | LmxM.10.0465 | gi 401416782 | mice | Protection | [ | |||
| Old world | LmTSI | Stress-induced protein sti1 | LmjF.08.1110 | gi 68124434 | mice | Protection | [ | ||
| GP63 | Metalloendopeptidase activity | LmjF.10.0470 | gi 157865341 | mice | Protection | [ | |||
| PSA 2 | Promastigote surface antigen protein 2 | LmjF.12.1000 | gi 68124979 | mice | No protection | [ | |||
| TSA | Thiol-specific-antioxidant—Tryparedoxin peroxidase | LmjF.15.1080 | gi 68125473 | mice | No protection | [ | |||
| Histone H1 | DNA binding | LmjF.27.1190 | gi 4008565 | mice | No protection | [ | |||
| LACK | LmjF.28.2740 | gi 157872022 | mice | Partial protection | [ | ||||
| New world | H2A | DNA binding | LinJ.21.1160 | gi 339898105 | mice | No protection | [ | ||
| LiCY1 | Peptidylprolyl isomerase | LinJ.25.0940 | gi 146088699 | mice | Partial protection | [ | |||
| Histone H1 | DNA binding | LinJ.27.1070 | gi 78146500 | mice | No protection | [ | |||
| CPC | Cysteine-type peptidase activity | LinJ.29.0860 | gi 146092987 | mice | Protection | [ | |||
| Old world | NH36 | Hydrolase activity | LdBPK_181570.1 | gi 19697561 | mice | Partial protection | [ | ||
| A2 | Amastigote-specific protein—stress response protein | LdBPK_220560.1 | gi 12382244 | mice | Protection | [ |
Number of binding Major Histocompatibility Complex (MHC) epitopes, B cell epitopes and subcellular localization predicted by different computational programs.
| MySQL ID | Prediction of Binding MHC Epitopes | Prediction of B Cells Epitopes | EO 1 | Prediction of Subcelular Localization | ||||
|---|---|---|---|---|---|---|---|---|
| Binding MHC Class I Epitopes | Binding MHC Class II Epitopes | AAP12 | BCPred12 | BepiPred | ||||
| NetMHC | NetCTL | NetMHCII | ||||||
| LbrM.15.1080 | 7 | 74 | 132 | 97 | 32 | 1 | No protection | cyt |
| LbrM.25.0580 | 6 | 31 | 121 | 75 | 23 | 2 | No protection | cyt |
| LbrM.28.2950 | 14 | 67 | 298 | 130 | 15 | 2 | Partial protection | nuc |
| A16600 | 4 | 18 | 63 | 21 | 9 | 2 | No protection | cyt |
| A22180 | 15 | 105 | 403 | 214 | 65 | 14 | Partial protection | ext |
| A38570 | 10 | 46 | 146 | 52 | 0 | 5 | No protection | ext |
| A64110 | 28 | 149 | 739 | 193 | 20 | 10 | Protection | ext |
| LmxM.10.0465 | 31 | 196 | 747 | 302 | 91 | 36 | Protection | ext |
| LmjF.08.1110 | 29 | 177 | 369 | 291 | 79 | 16 | Protection | cyt |
| LmjF.10.0470 | 27 | 177 | 668 | 317 | 52 | 19 | Protection | pla |
| LmjF.12.1000 | 23 | 100 | 475 | 226 | 102 | 12 | No protection | ext |
| LmjF.15.1080 | 9 | 77 | 199 | 81 | 35 | 5 | No protection | cyt |
| LmjF.27.1190 | 1 | 27 | 89 | 20 | 20 | 2 | No protection | nuc |
| LmjF.28.2740 | 16 | 64 | 301 | 172 | 18 | 7 | Partial protection | nuc |
| LinJ.21.1160 | 5 | 52 | 130 | 33 | 30 | 2 | No protection | nuc |
| LinJ.25.0940 | 8 | 26 | 116 | 98 | 69 | 2 | Partial protection | cyt |
| LinJ.27.1070 | 1 | 36 | 53 | 80 | 58 | 2 | No protection | nuc |
| LinJ.29.0860 | 21 | 99 | 331 | 201 | 85 | 4 | Protection | ext |
| LdBPK_181570.1 | 14 | 89 | 356 | 161 | 63 | 2 | Partial protection | ext |
| LdBPK_220560.1 | 35 | 159 | 669 | 200 | 165 | 12 | Protection | pla |
1 EO = Experimental outcome.
Figure 1Correlation analysis: (a) Box plots of the relationships between T CD4+, T CD8+ and B cell epitopes and experimental outcome of candidate antigens taking into account cutaneous leishmaniasis (CL); (b) box plots of the relationships between T CD4+, T CD8+ and B cell epitopes and experimental outcome of candidate antigens concerning leishmaniasis diseases with no stratification; and (c) correspondence map showing the association between experimental outcome and T CD4+, T CD8+ and B cell predicted epitopes for leishmaniasis with no stratification.
Figure 2Evaluation of epitopes amount and relationship with experimental outcome: (a) bar graph showing number of epitopes for MHC class I and II (haplotype d and b) in the selected antigens classified in “protection” and “no protection” groups; and (b) box plot of the relationships between CD4+ and CD8+ T cell epitopes and experimental outcome of candidate antigens.
Figure 3Immunogenic proteins mapped in Protein-Protein Interaction (PPI) networks: (a) PPI networks constructed starting with the target proteins (“no protection” and “partial protection/protection”) represented by triangles and specific pathways associated with each node (circles) using KEGG database. (b) Analysis of KEGG enriched pathways was performed by False Discovery Rate. For both “no protection” and “partial protection/protection”, the bar shows the fold-enrichment of the pathways. (c) Significant correlation between number of pathways connected with the target proteins of “no protection” and “partial protection/protection” groups (p = 0.007).
Leishmania predicted proteomes used in the study. The version and number of predicted proteins of each species are shown.
| Version of Proteome | Predicted Proteins | |
|---|---|---|
| 3.1 | 8357 | |
| - 1 | 8168 | |
| 9.0 | 8250 | |
| 9.0 | 8400 | |
| 8.0 | 8083 | |
| 3.2 | 8241 |
1 This is a draft version. This proteome still has many annotation errors.
Figure 4Workflow of analysis showing the steps followed along this work.
Figure 5MySQL relational database scheme developed to integrate data from predictions.